Top FDA Drug Regulator’s Unusual Criticism of a Therapy Gets Wall Street Wagging

Aurinia Responds to Now Retracted LinkedIn Post

ROCKVILLE, Md. & EDMONTON, Alberta -- Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today responded to a now retracted LinkedIn post referencing voclosporin by an FDA official.

Top FDA drug regulator’s unusual criticism of a therapy gets Wall Street wagging

George Tidmarsh, the head of the FDA's CDER division, has a personal connection to Kevin Tang, the largest investor in the company that makes the drug.

Pharma company Aurinia falls after FDA official uses LinkedIn to call out lupus drug

Lupkynis, which was approved in 2021, is Aurinia’s primary source of revenue....

Updated: CDER director says FDA to take 'close look' at use of surrogate endpoints, calls out Aurinia drug

George Tidmarsh, director of the FDA's drug center, said in a now-deleted social media post that the agency would reconsider the use of surrogate endpoints that have been used to approve drugs more quickly than ...